Efpeglenatide and Heart and Kidney Outcomes in...

Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes

Abstract

To the Editor: In the AMPLITUDE-O trial, Gerstein et al. (Sept. 2 issue)1 found a lower risk of cardiovascular events among participants with type 2 diabetes who received a weekly injection of efpe...

Authors

Borderie G; Schnebelen M; Baynat L

Journal

The New England Journal of Medicine, Vol. 385, No. 22, pp. 2105–2107

Publisher

Massachusetts Medical Society

Publication Date

November 25, 2021

DOI

10.1056/nejmc2115776

ISSN

0028-4793

Associated Experts

Hertzel Chaim Gerstein

Professor, FHSMED

Visit profile

Labels

Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes

Abstract

Authors

Journal

Publisher

Publication Date

DOI

ISSN

Associated Experts

Labels

Fields of Research (FoR)

Sustainable Development Goals (SDG)

Medical Subject Headings (MeSH)

Contact the Experts team